Introduction {#s1}
============

Improved survival coupled with a decline in the incidence of acute myocardial infarction (AMI)^[@QCW003C1],[@QCW003C2]^ has dramatically changed the pattern of healthcare use over recent years.^[@QCW003C3],[@QCW003C4]^ Nowadays, patients with stable coronary artery disease (SCAD), including patients with stable angina and those who have become stable after acute coronary syndrome (ACS),^[@QCW003C5],[@QCW003C6]^ are older and living longer and so make greater use of healthcare resources. Patients with SCAD might be considered to have 'fallen off the radar' of clinical interest: no longer in cardiac rehabilitation \[mainly offered to those immediately after AMI or coronary artery bypass grafting (CABG)\], discharged from ongoing specialist care, and with suboptimal drug compliance, adherence, and persistence.^[@QCW003C7]^ Such patients, however, vary widely in their risk of subsequent AMI or coronary death (∼10-fold, between top and bottom deciles of risk),^[@QCW003C8]^ which will clearly have differential resource implications.

While previous studies of resource use and cost have taken as a starting point AMI,^[@QCW003C9],[@QCW003C10]^ there is a paucity of information about the contemporary use and associated costs of healthcare beyond the initial hospital stay. In addition, existing studies in the area have been limited in a number of ways. First, as a result of the nature of their samples, they are not population based and do not reflect contemporary and routine clinical practice.^[@QCW003C11]^ Second, they use overly simplistic models, typically restricting their analysis to a subset of SCAD index events and not evaluating how the pattern of healthcare resource use changes following a first post-SCAD myocardial infarction (MI) or stroke.^[@QCW003C9],[@QCW003C10]^ Third, no study has evaluated resource utilization and costs according to baseline cardiovascular risk, despite the importance of this information in improving decision-making and ensuring more efficient use of limited healthcare resources. Fourth, longer term and particularly lifetime implications of SCAD have not been quantified.

These knowledge gaps have a number of important ramifications. They create uncertainty for those who need to forecast future care needs, restrain the research and development of new technologies and treatments for SCAD, and limit informed clinical decision-making. To address these limitations, our study aimed to (i) determine healthcare utilization and the associated costs in the first year with SCAD and in the year following a first non-fatal event (i.e. AMI, ischaemic or haemorrhagic stroke), (ii) study predictors of costs in the first year of SCAD, and (iii) estimate the 5-year and lifetime costs among patients at low and high risk of subsequent events and coronary heart disease (CHD) death.

Methods {#s2}
=======

Data set and patient population {#s2a}
-------------------------------

The ClinicAl research using Linked Bespoke studies and Electronic Records (CALIBER) e-health database was the data resource for this study. CALIBER links patient records from four different data sources: Clinical Practice Research Database (CPRD), Myocardial Ischaemia National Audit Project (MINAP) registry, Hospital Episodes Statistics (HES), and the Office for National Statistics. The data of CPRD were used to obtain heart rate measurements, demographic variables, and other risk factors. Primary care practices that provide valuable data to CPRD and cover ∼4% of UK population are representative in terms of demographic parameters such as gender, age, and ethnicity^[@QCW003C12],[@QCW003C13]^ and overall mortality^[@QCW003C14]^ and have been validated for epidemiological research. A description of the CALIBER approach has been presented elsewhere.^[@QCW003C15]^ Classification algorithms combining Read, International Classification of Disease 10 (ICD-10), drug, and procedure codes to define risk factors and endpoints are available at <http://www.caliberresearch.org/portal/>.

Eligible patients were those with a diagnosis of stable angina, patients with a diagnosis of ACS within the study period (unstable angina or AMI), or those with a diagnosis of CHD in which there is no further specification of whether it is angina or MI (other CHD). Study start date was calculated from the date of diagnosis of stable angina or other CHD or from 6 months after an ACS or coronary intervention. The period of 6 months was chosen to differentiate long-term prognosis from the high-risk period that typically follows an ACS or revascularization. Diagnoses were identified in CPRD, HES, or MINAP records according to definitions given in the CALIBER data manual.^[@QCW003C15]^ Patients were only eligible for the study during the period they were actively registered at a CPRD practice that was collecting up-to-standard data (according to CPRD measures of data quality and completeness), with follow-up ending if a patient transferred out of a CPRD practice. Full details of the cohort are available elsewhere.^[@QCW003C8]^

Healthcare utilization {#s2b}
----------------------

Healthcare utilization extracted from the data set included primary care consultations, pharmaceutical prescriptions, inpatient stays, and diagnostic tests. Primary care consultations included all contacts between the patient and healthcare professionals captured in the CPRD data set. Prescription data were available from the CPRD data set and distinguished between drugs that were cardiovascular disease (CVD)-related and those that were not. Inpatient stays extracted from HES were based on Health Resource Group (HRG) codes and defined as CHD, CVD (including CHD and broader HRGs), or non-CVD related based on ICD-10 codes. Diagnostic tests as recorded in the primary care data set but not outpatient consultations were also extracted, the latter being due to the absence of outpatient HES data linkage.

Costs {#s2c}
-----

All costs were calculated from the perspective of the UK National Health Service (NHS) in pound sterling based on 2011/12 prices. Costs were calculated by combining healthcare utilization data from CALIBER with associated unit costs that were taken from published UK sources.^[@QCW003C16]^ For hospitalizations, costs are calculated based on finished consultant episodes in HES. Costs are presented in terms of total healthcare costs (all costs incurred), CHD costs (all CHD-related hospitalization costs, CVD-related drugs, and all primary care and diagnostic costs), and CVD costs (all CVD-related hospitalization costs, CVD-related drugs, and all primary care and diagnostic costs).

Analytical methods {#s2d}
------------------

Estimates of healthcare utilization and costs were calculated for the first year in the SCAD cohort and the first year following a non-fatal event during the follow-up period (AMI, ischaemic or haemorrhagic stroke) with results reported as means and standard deviations, with medians and interquartile ranges reported in the appendices. Observations that were right censored for any reason other than mortality (i.e. those for which the data are incomplete for the year of interest, either first year with SCAD or first year following an event, but the reason for incompleteness was not death) were excluded from the analysis.

A generalized linear model with a log link and gamma distribution was used to estimate the impact of baseline covariates on costs in the first year in the SCAD cohort to account for the non-linear impact of covariates and the right skewness in cost data. Covariates were based on those used by Rapsomaniki *et al*.,^[@QCW003C8]^ which developed a prognostic model for SCAD patients, on the assumption that predictors of costs were likely linked to prognostic indicators. The covariates included the baseline diagnosis for entry to SCAD, co-morbidities, age, gender, smoking status, and biomarkers. Models were fitted on five multiply-imputed data sets and estimates combined using Rubin\'s rules.^[@QCW003C19]^ The impact of covariates has been transformed back onto the natural scale to allow for ease of interpretation.

Panel data methods with time invariant covariates were used to estimate patient costs over each 90-day period. Also estimated were the impact of events (non-fatal AMI, ischaemic and haemorrhagic stroke, CVD- and non-CVD-related death) on the costs in the period of the event and subsequent periods if the event was non-fatal. These costs were then combined with a state transition Markov model to estimate costs over a longer period. The model estimated the probabilities of, and mean times to, the first events of non-fatal AMI, ischaemic or haemorrhagic stroke, CVD- and non-CVD-related death, and subsequent CVD or non-CVD death following a non-fatal first event. These estimates were conditional on baseline covariates and were inferred from patient-level costs, covariates, survival, and events experienced. Full details of this model are available elsewhere with a brief description given in the appendix.^[@QCW003C20]^ For the purpose of this article, the results of costs over time are presented for patients based on average covariate patterns for the 5-year risk deciles of a cardiovascular event. Discounted costs are also presented using a discount rate of 3.5% per annum.^[@QCW003C21]^

Results {#s3}
=======

Cohort {#s3a}
------

In total, 94 966 patients were identified who met the inclusion criteria, of which 44% were female. The mean age of men and women included were 67 and 72 years, respectively. For the primary SCAD diagnosis, 47.4% of patients had stable angina, 13.5% unstable angina, 6.7% ST-elevation MI (STEMI), 9.7% non-STEMI (NSTEMI), and 22.6% had CHD not otherwise specified. Full details of the cohort can be found in Appendix *Table [A1](#QCW003TB4){ref-type="table"}*.

*Figure [1](#QCW003F1){ref-type="fig"}* summarizes the SCAD cohort and the patient numbers used for each analysis.

![Stable coronary artery disease cohort.](qcw00301){#QCW003F1}

Healthcare utilization {#s3b}
----------------------

*Table [1](#QCW003TB1){ref-type="table"}* reports healthcare utilization in the first year in the SCAD cohort and in the first year following a non-fatal event during the follow-up period (AMI, ischaemic or haemorrhagic stroke). In the first year in the SCAD cohort, 20.5% of patients (*n* = 17 532) were hospitalized for CVD, and those who were hospitalized had a mean 1.9 stays (spells) in hospital with a mean length of stay of 4.6 days. In the year following a non-fatal event during follow-up, 66% of patients (*n* = 4354) were hospitalized for CHD. These patients spent a mean of 2.2 stays in hospital with a mean length of stay of 6.5 days. In the first year in SCAD, patients had a mean of 10.8 primary care appointments, and this increased to 13.7 in the first year following a non-fatal event. In the first year of SCAD, 88.2% of patients were taking cardiovascular medication, which decreased to 83.6% in the year following a non-fatal event. In the first year of SCAD, 5.7% of patients had a revascularization procedure, increasing to 13.5% of patients in the first year following a non-fatal event.

###### 

Healthcare utilization in first year in the stable coronary artery disease cohort and first year following a non-fatal event during follow-up (myocardial infarction, ischaemic or haemorrhagic stroke)

                                              Resource use in first year (*n*= 85 702)   Resource in first year following an event (*n* = 6599)
  ------------------------------------------- ------------------------------------------ --------------------------------------------------------
  Hospitalizations                                                                       
   Hospitalized (%)                           37.6 (0.484)                               83.5 (0.371)
   Hospitalized for CVD (%)                   27 (0.444)                                 80.2 (0.399)
   Hospitalized for CHD (%)                   20.5 (0.403)                               66 (0.474)
   Inpatient stays                            0.875 (4.421)                              2.364 (6.425)
   Inpatient stays for CVD                    0.503 (2.545)                              1.931 (5.284)
   Inpatient stays for CHD                    0.343 (1.321)                              1.434 (3.315)
  With any hospitalization                    *n* = 32 242                               *n* = 5512
   Inpatient stays                            2.325 (6.971)                              2.83 (6.935)
   Length of stay                             6.717 (17.583)                             14.857 (20.349)
  With any hospitalization for CVD            *n* = 23 160                               *n* = 5291
   Inpatient stays for CVD                    1.862 (4.631)                              2.408 (5.803)
   Length of stay                             7.516 (12.757)                             15.541 (20.939)
  With any hospitalization for CHD            *n* = 17 532                               *n* = 4354
   Inpatient stays for CHD                    1.674 (2.51)                               2.174 (3.88)
   Length of stay                             4.579 (7.617)                              6.515 (10.857)
  Revascularizations                                                                     
   Any revascularization (%)                  5.7 (0.232)                                13.5 (0.341)
   PCI (%)                                    3 (0.17)                                   9.1 (0.287)
   CABG (%)                                   2.9 (0.169)                                5 (0.218)
  Primary care consultations                  10.768 (10.857)                            13.671 (15.407)
  Drugs                                                                                  
   Patients on any drugs (%)                  91.3 (0.281)                               85.1 (0.356)
   Patients on CVD drugs (%)                  88.2 (0.322)                               83.6 (0.37)
   Patients on anticoagulants (%)             8.7 (0.282)                                14.7 (0.354)
   Patients on ACEi or ARB (%)                47.7 (0.499)                               61.5 (0.487)
   Patients on anti-platelets (%)             65.6 (0.475)                               76.3 (0.425)
   Patients on β-blockers (%)                 46 (0.498)                                 50.1 (0.5)
   Patients on calcium channel blockers (%)   31.5 (0.464)                               32.6 (0.469)

Costs {#s3c}
-----

*Table [2](#QCW003TB2){ref-type="table"}* reports costs for hospitalizations, primary care appointments, diagnostic tests, and drugs in patients in the first year in the SCAD cohort, and in the first year following a non-fatal event during follow-up (MI, ischaemic or haemorrhagic stroke). The mean total healthcare costs in the first year in the SCAD cohort were £3133 per patient, of which 56.8% (£1780) and 70.2% (£2199) were related to CHD and CVD, respectively. This estimate increased to £10 377 per patient in the year following a non-fatal event during follow-up, of which 66.2% (£6869) and 85.9% (£8916) were related to CHD and CVD, respectively. The majority of healthcare costs were driven by hospitalizations (64.4% in the first year in the SCAD cohort and 84.2% in the year following a non-fatal event during follow-up).

###### 

Costs in first year in the stable coronary artery disease cohort and in first year following an event during follow-up (myocardial infarction, ischaemic or haemorrhagic stroke)

                              Costs in first year (*n* = 85 702)   Costs in first year following an event (*n* = 6599)
  --------------------------- ------------------------------------ -----------------------------------------------------
  Total costs                                                      
   Total cost (£)             3133 (6101)                          10 377 (12 260)
   Total CVD cost (£)         2199 (4632)                          8916 (10 930)
   Total CHD costs (£)        1780 (3686)                          6869 (9467)
  Hospitalizations                                                 
   Inpatient costs (£)        2018 (5632)                          8744 (11 554)
   Inpatient CVD costs (£)    1487 (4493)                          7957 (10 796)
   Inpatient CHD costs (£)    1067 (3548)                          5910 (9338)
  Primary care costs (£)      466 (463)                            589 (629)
  Diagnostic test costs (£)   141 (232)                            228 (311)
  Drugs                                                            
   All drug costs (£)         508 (1548)                           816 (3135)
   CVD drug costs (£)         105 (113)                            142 (175)

Cost predictors in the first year in the stable coronary artery disease cohort {#s3d}
------------------------------------------------------------------------------

*Figure [2](#QCW003F2){ref-type="fig"}* presents the results of the regression analysis showing the incremental costs associated with different covariates and the associated 95% confidence intervals (CI) for the first year in the SCAD cohort. Non-CVD-related co-morbidities had the largest impact on costs, with a history of renal disease associated with the largest increment of £1998 per patient (95% CI £1715--£2297). A history of heart failure resulted in an additional cost of £802 per patient (95% CI £683--£920). Of the baseline diagnoses for entry to the SCAD cohort, NSTEMI had the largest impact on cost with those patients with NSTEMI costing an additional £656 per patient (95% CI £473--£848) when compared with those with stable angina. Females were significantly less costly than males, being female was associated with a cost decrement of £549 per patient (95% CI −£638 to −£457). *Figures [A1](#QCW003F4){ref-type="fig"}* and *[A2](#QCW003F5){ref-type="fig"}* in the appendix present the same results for CVD- and CHD-related costs, respectively.

![Forest plot of incremental costs associated with covariates.](qcw00302){#QCW003F2}

Estimated 90-day period and event costs {#s3e}
---------------------------------------

*Tables [A4](#QCW003TB7){ref-type="table"}*, *[A5](#QCW003TB8){ref-type="table"}*, and *[A6](#QCW003TB9){ref-type="table"}* in the appendix provide estimates of total healthcare costs, CVD-related costs, and CHD-related costs, respectively, for a 90-day period based on a range of baseline characteristics. The tables also show the incremental costs in the period of an event and in subsequent periods for non-fatal events. For example, the background total healthcare costs for a male, mean age 69 years, with no co-morbidities would be £341 in the first 90 days, increasing by £10 for each subsequent 90-day period. If the patient had a non-fatal AMI, he would incur an incremental cost (on top of the normal period cost of £372) of £5028 in the 90 days following the AMI with the incremental costs decreasing in subsequent trimesters until 360 days after which there is an incremental cost of £521 per 90 days suggesting significant ongoing lifetime costs of events. Also of note, the incremental costs in the period of death from CVD- and non-CVD-related causes were £2008 and £2240, respectively.

Estimated costs over time for stable coronary artery disease {#s3f}
------------------------------------------------------------

*Table [3](#QCW003TB3){ref-type="table"}* presents estimates of 5-year and lifetime costs (total and CVD related, undiscounted and discounted) of the representative patients for each risk group. The covariate profiles used are shown in Appendix *Table [A7](#QCW003TB10){ref-type="table"}*.

###### 

Mean 5-year and lifetime costs for stable coronary artery disease patient population by cardiovascular risk decile

  Results                                      Risk group                                                                           
  -------------------------------------------- ------------ -------- -------- -------- -------- -------- -------- -------- -------- --------
  5-year risk^a^ (%)                           3.46         5.43     6.95     8.53     10.36    12.57    15.64    20.07    27.23    44.18
  Average age (years)                          52           59       62       65       68       70       73       76       80       84
  Life expectancy (years)                      26.81        19.62    17.34    15.63    14.26    13.03    11.92    10.48    8.52     5.51
  Total 5-year costs (£)                       9335         11 200   12 308   13 512   14 644   15 930   17 660   19 609   21 617   23 391
  Discounted total 5-year costs^b^ (£)         8495         10 204   11 221   12 327   13 368   14 554   16 153   17 963   19 853   21 620
  Total 5-year CVD costs (£)                   5306         6959     7941     8954     9874     10 904   12 242   13 742   15 380   17 050
  Discounted total 5-year CVD costs^b^ (£)     4823         6338     7238     8168     9014     9962     11 197   12 589   14 126   15 759
  Total 5-year CHD costs (£)                   4172         5543     6354     7153     7867     8583     9449     10 385   11 376   12 392
  Discounted total 5-year CHD costs^b^ (£)     3801         5057     5801     6534     7191     7850     8651     9521     10 455   11 459
  Total lifetime costs (£)                     116 888      81 490   73 057   68 102   64 521   62 034   61 435   59 446   54 345   43 020
  Discounted total lifetime costs^b^           62 210       50 864   48 046   46 535   45 429   44 785   45 283   44 903   42 436   35 549
  Total lifetime CVD costs (£)                 71 943       52 034   47 681   45 251   43 438   42 266   42 301   41 366   38 410   31 199
  Discounted total lifetime CVD costs^b^ (£)   37 857       32 331   31 288   30 896   30 584   30 531   31 211   31 281   30 024   25 801
  Total lifetime CHD costs (£)                 46 921       36 069   33 892   32 693   31 741   30 944   30 793   29 885   27 533   22 324
  Discounted total lifetime CHD costs^b^ (£)   25 316       22 868   22 639   22 672   22 657   22 619   22 946   22 778   21 646   18 522

^a^Of AMI, ischaemic or haemorrhagic stroke, or fatal CVD.

^b^Discounted at a rate of 3.5% per annum to calculate the present value of the costs.

A patient with SCAD representative of the lowest risk decile (5-year cardiovascular risk of 3.5% and a life expectancy of 26.8 years) would have expected undiscounted costs of £9335 over 5 years, of which 44.7 and 56.8% would be CHD and CVD related, respectively; and undiscounted lifetime costs of £116 888, of which 40.1 and 61.5% would be CHD and CVD related, respectively. A representative patient of the highest risk decile (5-year cardiovascular risk of 44.2% and a life expectancy of 5.51 years) would have expected undiscounted costs of £23 391 over 5 years, of which 53.0 and 72.9% would be CHD and CVD related, respectively; and lifetime undiscounted costs of £43 020, of which 51.9 and 72.5% would be CHD and CVD related, respectively.

*Figure [3](#QCW003F3){ref-type="fig"}* shows the predicted total, CVD-related, and CHD-related costs and the survival curves over a 25-year period for representative patients of risk deciles 1 (lowest risk), 4, 7, and 10 (highest risk). Higher risk patients with SCAD have higher initial costs, which are overtaken by the lower risk patients as a result of higher mortality in the higher risk groups resulting in less time to accrue costs (5-year survivorship differs from 98.4% in risk decile 1 to 40.7% in risk decile 10; and 25-year survivorship differs from 58.2% in risk decile 1 to 0.5% in risk decile 10).

![Expected costs and survival over time for patients representative of risk deciles 1, 4, 7, and 10. CHD, coronary heart disease; CVD, cardiovascular disease; RG, risk decile.](qcw00303){#QCW003F3}

Discussion {#s4}
==========

This study addresses a fundamental gap in knowledge relevant to clinicians and policymakers: what is the clinical, health service, and cost burden associated with SCAD? Using data from a large, contemporary, and representative population of patients from the England with SCAD, the analysis has shown that substantial healthcare costs are likely to be incurred as a result of improved ACS survivorship and the ageing population. Moreover, 5-year and lifetime costs vary according to CVD risk, which may be readily predicted from the baseline characteristics of patients that are routinely collected. High-risk patients have considerably higher costs over the initial 5 years but lower lifetime costs than lower risk patients as a result of shorter life expectancy.

Patients with SCAD might be considered to have 'fallen off the radar' of clinical interest. Current guidelines give little information about how frequently and where such patients should be followed up or if and how they should be risk stratified.^[@QCW003C5],[@QCW003C6]^ Our results clearly highlight the unmet need and the shortfalls of current approaches---with high use of primary care and frequent hospitalizations, there are considerable ongoing costs. The number of primary care consultations, a mean of 10.8 per patient in the first year in the SCAD cohort, is higher than previous estimates for the overall population (5.5 per year).^[@QCW003C22]^ In the first year in the SCAD cohort, over a third of patients were hospitalized (and 20.5% for CHD reasons). This is substantially higher than recent estimates for the general population in one area of the UK (14.9%),^[@QCW003C23]^ and markedly higher than that in the general population for a similar age (23.4 and 21.2% of 60- to 74-year-old males and females, respectively, based on HES data).

Healthcare utilization is, however, insufficient as a metric of the impact on the healthcare system. It is also important to consider the cost imposed on the NHS associated with those resources as this indicates the value of resources that cannot be devoted to health-enhancing activities for other patients. Mean costs of £3133 in the first year in the SCAD cohort are much higher than those in patients without chronic conditions (£293), but comparable with other chronic conditions (e.g. diabetes £3036).^[@QCW003C23]^ Very high costs in the first year following a non-fatal event during follow-up (MI, ischaemic or haemorrhagic stroke) (£10 377) are reflective of the healthcare utilization required to treat that event.

Patients were stratified by risk to understand the costs accrued in greater detail. This higher resolution analysis allows the identification of where novel treatments and health service interventions have the greatest potential to be cost-effective. Non-CVD co-morbidities were common and had a major influence on costs with e.g. renal disease resulting in a mean extra cost of £1998 per patient in the first year of SCAD. This is an important finding when the presence of multiple co-morbidities has been shown to increase costs^[@QCW003C23]^ yet clinicians tend to focus only on single diseases.^[@QCW003C24]^

The panel data analysis examined the average cost per 90-day period with the disease and also the costs of events. The estimated incremental cost of a non-fatal MI over 1 year (£7677 ignoring mortality risk) was lower than some previous estimates from trial populations (e.g. among patients with stable angina the estimate of £9775 from the EUROPA trial).^[@QCW003C11]^ However, this lower estimate may be reflective of less intensive use of healthcare resources in non-trial settings and should provide a more accurate representation of costs of these events in routine clinical practice. Estimated stroke costs in the first year of the event (£8902 for ischaemic and £10 477 for haemorrhagic stroke incremental to background costs) were similar to those seen in other studies. For example, the OXVASC study estimated mean total healthcare costs per patient in the first year following stroke at £10524.^[@QCW003C25]^

Furthermore, a study of costs in the first year of SCAD and the first year following an event is of limited use to decision-makers who require more detailed information on the long-term costs and consequences of SCAD. This can be seen from the panel data analysis, which suggested ongoing long-term costs as a result of non-fatal events. By estimating 5-year and lifetime costs by CVD risk group, it was possible to examine the long-term cost implications as a result of the disease and future events. In the shorter term of 5 years, which is shorter than the life expectancy of even the highest risk group (although survivorship in this group was only 40.7% at 5 years), costs increased with cardiovascular risk, and were largely driven by the high number of fatal and non-fatal events among these patients. Over a lifetime, however, patients in the lower risk groups eventually had substantially higher costs than higher risk patients, primarily driven by greater life expectancy and, therefore, costs being incurred over a much longer period. This is a key finding of our research: increased survivorship as well as an increasingly co-morbid and older population will result in significant future healthcare costs. In turn, this has implications for the cost and therefore the cost-effectiveness of established and new SCAD treatments.

Many studies have attempted to address the burden of disease in terms of health losses but fewer have examined the impact on financial costs of disease. Our research used SCAD as an exemplar in estimating resource use and costs from 'real world' electronic health record data. The methods used here could be readily applied to other chronic diseases to help produce evidence of their resource and cost implications to better inform clinicians and decision-makers. This would reduce uncertainty for those who need to forecast future care needs and allow for better focused research and development of new technologies and treatments for these chronic diseases as well as resulting in better informed clinical decision-making.

Limitations {#s4a}
-----------

While our study has a number of strengths including the multi-source electronic health record linkage, there are a number of limitations. In addition to being censored at 2010, after which there have been further improvements in the care and survivorship of SCAD, a key weakness of this study was the exclusion of outpatient appointment costs that cannot currently be linked from HES. As a result, the total healthcare costs of this population are underestimated. Further disaggregation of primary care costs into CHD and CVD related was not possible and therefore in each category all primary care costs have been included and therefore are likely overestimated. The estimation of lifetime costs has also involved extrapolation over a longer time period than is currently observed in the CALIBER data. This extrapolation is subject to considerable uncertainty. The SCAD population is also inherently heterogeneous, and there may be value in further disaggregation of the population in future research.

Conclusions {#s5}
===========

Using a multi-source electronic health record approach, this study provides, for the first time, estimates and predictors of contemporary national healthcare utilization and costs in the first year of SCAD and the first year following an event. It reveals that patients with SCAD incur substantial healthcare utilization and costs, which vary and may be predicted by 5-year CVD risk profiles. While high-risk patients incur substantially higher costs over the short term (5 years), low-risk patients incur higher lifetime costs as a result of greater life expectancy. Improved cardiovascular survivorship and an ageing UK population will require stratified care in anticipation of the burgeoning economic demand. The methods used here could be readily applied to other chronic diseases to better inform clinical decision-making.
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Model description {#s8}
=================

A state transition Markov model was used to capture the natural history of SCAD patients. The model predicts time to first non-fatal events (MI, ischaemic stroke or haemorrhagic stroke) and CVD and non-CVD mortality (as a first event or following a non-fatal first event). The model has a lifetime horizon and uses a 90-day cycle length to capture the time varying and age-dependent nature of risks. Risks of the five primary clinical endpoints (non-fatal MI, non-fatal ischaemic stroke, non-fatal haemorrhagic stroke, and CVD and non-CVD mortality) were estimated based on key prognostic factors, including demographic measures, SCAD subtype, use of long-acting nitrates, whether CABG or PCI was performed in the 6 months following CAD diagnosis, previous MI, smoking, blood pressure, diagnosis of hypertension, diabetes, lipids, CVD co-morbidities, non-CVD co-morbidities, psychosocial factors, and clinically assessed biomarkers. Risk equations for the six subsequent events, namely CVD and non-CVD mortality following non-fatal MI, ischaemic stroke, and haemorrhagic stroke were estimated in a similar way. However, due to the greatly reduced numbers of events observed, these were based only on sex and age at time of non-fatal event. Non-CVD mortality beyond the maximum follow-up in the CALIBER data set (10 years) was based on age--sex-specific non-CVD mortality from national life tables. Costs are accrued based on baseline covariate, events experienced, and time alive with the costs based on the results detailed in this article. Full details can be found in Asaria *et al*.^[@QCW003C20]^

###### 

Patient characteristics

  Socio-demographic characteristics                 
  ------------------------------------------------- ----
  Sex (% female)                                    44
  Age (if male) (years)                             67
  Age (if female) (years)                           72
  Most deprived quintile (%)                        20
  Baseline diagnoses for entry to the SCAD cohort   
   NSTEMI (%)                                       10
   STEMI (%)                                        7
   Unstable angina (%)                              14
   Stable angina (%)                                47
   CHD not otherwise specified (%)                  23
  CVD risk factors                                  
   Current smoker (%)                               35
   Ex-smoker (%)                                    32
   Never smoked (%)                                 33
   Hypertension (%)                                 76
   Diabetes (%)                                     16
  CVD co-morbidities                                
   Heart failure (%)                                26
   Atrial fibrillation (%)                          15
   Peripheral arterial disease (%)                  8
   Stroke (%)                                       9

###### 

Healthcare utilization in first year with stable coronary artery disease and first year following a non-fatal event (myocardial infarction, ischaemic or haemorrhagic stroke)

                                                           Mean (SD)         Median (IQR)
  -------------------------------------------------------- ----------------- -----------------
  Resource use in first year (*n* = 85 702)                                  
  Hospitalizations                                                           
   Hospitalized (%)                                        37.6 (0.484)      0 (0--1)
   Hospitalized for CVD (%)                                27 (0.444)        0 (0--1)
   Hospitalized for CHD (%)                                20.5 (0.403)      0 (0--1)
   Inpatient stays                                         0.875 (4.421)     0 (0--3)
   Inpatient stays for CVD                                 0.503 (2.545)     0 (0--2)
   Inpatient stays for CHD                                 0.343 (1.321)     0 (0--2)
  With any hospitalization (*n* = 32 242)                                    
   Inpatient stays                                         2.325 (6.971)     1 (1--5)
   Length of stay                                          6.717 (17.583)    3 (1--23)
  With any hospitalization for CVD (*n* = 23 160)                            
   Inpatient stays for CVD                                 1.862 (4.631)     1 (1--4)
   Length of stay                                          7.516 (12.757)    3.667 (1--26)
  With any hospitalization for CHD (*n* = 17 532)                            
   Inpatient stays for CHD                                 1.674 (2.51)      1 (1--4)
   Length of stay                                          4.579 (7.617)     2 (1--14.75)
  Revascularizations                                                         
   Any revascularization (%)                               5.7 (0.232)       0 (0--1)
   PCI (%)                                                 3 (0.17)          0 (0--0)
   CABG (%)                                                2.9 (0.169)       0 (0--0)
  Primary care consultations                               10.768 (10.857)   8 (0--30)
  Drugs                                                                      
   Patients on any drugs (%)                               91.3 (0.281)      1 (0--1)
   Patients on CVD drugs (%)                               88.2 (0.322)      1 (0--1)
   Patients on anticoagulants (%)                          8.7 (0.282)       0 (0--1)
   Patients on ACEi or ARB (%)                             47.7 (0.499)      0 (0--1)
   Patients on anti-platelets (%)                          65.6 (0.475)      1 (0--1)
   Patients on β-blockers (%)                              46 (0.498)        0 (0--1)
   Patients on calcium channel blockers (%)                31.5 (0.464)      0 (0--1)
  Resource in first year following an event (*n* = 6599)                     
  Hospitalizations                                                           
   Hospitalized (%)                                        83.5 (0.371)      1 (0--1)
   Hospitalized for CVD (%)                                80.2 (0.399)      1 (0--1)
   Hospitalized for CHD (%)                                66 (0.474)        1 (0--1)
   Inpatient stays                                         2.364 (6.425)     1 (0--6)
   Inpatient stays for CVD                                 1.931 (5.284)     1 (0--5)
   Inpatient stays for CHD                                 1.434 (3.315)     1 (0--4)
  With any hospitalization (*n* = 5512)                                      
   Inpatient stays                                         2.83 (6.935)      2 (1--6)
   Length of stay                                          14.857 (20.349)   8.5 (1.5--50.5)
  With any hospitalization for CVD (*n* = 5291)                              
   Inpatient stays for CVD                                 2.408 (5.803)     2 (1--5)
   Length of stay                                          15.541 (20.939)   9 (2--52)
  With any hospitalization for CHD (*n* = 4354)                              
   Inpatient stays for CHD                                 2.174 (3.88)      1 (1--5)
   Length of stay                                          6.515 (10.857)    3.5 (1--21.5)
  Revascularizations                                                         
   Any revascularization (%)                               13.5 (0.341)      0 (0--1)
   PCI (%)                                                 9.1 (0.287)       0 (0--1)
   CABG (%)                                                5 (0.218)         0 (0--1)
  Primary care consultations                               13.671 (15.407)   11 (0--38)
  Drugs                                                                      
   Patients on any drugs (%)                               85.1 (0.356)      1 (0--1)
   Patients on CVD drugs (%)                               83.6 (0.37)       1 (0--1)
   Patients on anticoagulants (%)                          14.7 (0.354)      0 (0--1)
   Patients on ACEi or ARB (%)                             61.5 (0.487)      1 (0--1)
   Patients on anti-platelets (%)                          76.3 (0.425)      1 (0--1)
   Patients on β-blockers (%)                              50.1 (0.5)        1 (0--1)
   Patients on calcium channel blockers (%)                32.6 (0.469)      0 (0--1)

###### 

Costs in first year with stable coronary artery disease and in first year following an event (myocardial infarction, ischaemic of haemorrhagic stroke)

                                                        Mean (SD) (£)     Median (IQR) (£)
  ----------------------------------------------------- ----------------- --------------------
  Costs in first year (*n* = 85 702)                                      
   Total costs                                                            
    Total cost                                          3133 (6101)       1149 (43--12 641)
    Total CVD cost                                      2199 (4632)       735 (0--10 274)
    Total CHD costs                                     1780 (3686)       685 (0--8413)
   Hospitalizations                                                       
    Inpatient costs                                     2018 (5632)       0 (0--10 603)
    Inpatient CVD costs                                 1487 (4493)       0 (0--9333)
    Inpatient CHD costs                                 1067 (3548)       0 (0--7284)
   Primary care costs                                   466 (463)         361 (0--1291)
   Diagnostic test costs                                141 (232)         70 (0--538)
   Drugs                                                                  
    All drug costs                                      508 (1548)        209 (0--1698)
    CVD drug costs                                      105 (113)         84 (0--272)
  Costs in first year following an event (*n* = 6599)                     
   Total costs                                                            
    Total cost                                          10 377 (12 260)   6855 (580--30 755)
    Total CVD cost                                      8916 (10 930)     5819 (384--27 279)
    Total CHD costs                                     6869 (9467)       3972 (159--23 336)
   Hospitalizations                                                       
    Inpatient costs                                     8744 (11 554)     5421 (0--27 436)
    Inpatient CVD costs                                 7957 (10 796)     4871 (0--25 843)
    Inpatient CHD costs                                 5910 (9338)       3127 (0--22 020)
   Primary care costs                                   589 (629)         456 (0--1664)
   Diagnostic test costs                                228 (311)         131 (0--806)
   Drugs                                                                  
    All drug costs                                      816 (3135)        293 (0--2924)
    CVD drug costs                                      142 (175)         110 (0--376)

###### 

Total healthcare costs per 90-day period

                                                                                 Coefficient (£)   Standard error   Lower 95% CI (£)   Upper 95% CI (£)
  ------------------------------------------------------------------------------ ----------------- ---------------- ------------------ ------------------
  Background cost per 90 days                                                                                                          
   Baseline (for a man aged 69 with stable angina and no other co-morbidities)   341               10.15            322                361
   Baseline age (centred)                                                        7                 0.42             6                  7
   Female                                                                        −7                10.09            −26                13
   Increase per 90 days                                                          10                0.18             10                 11
   SCAD diagnosis (relative to stable angina)                                                                                          
    Other CHD                                                                    −20               12.40            −44                5
    NSTEMI                                                                       157               18.37            121                193
    STEMI                                                                        −26               21.48            −68                17
    Unstable angina                                                              153               14.92            124                183
   CVD co-morbidities                                                                                                                  
    History of heart failure                                                     364               12.23            340                388
    History of atrial fibrillation                                               186               14.32            158                214
    History of PAD                                                               327               17.80            292                362
   Non-CVD co-morbidities                                                                                                              
    Diabetes                                                                     338               13.71            312                365
    History of liver disease                                                     530               50.70            431                629
    History of COPD                                                              231               11.58            208                254
    History of cancer                                                            331               17.51            296                365
    History of renal disease                                                     756               20.93            715                797
  Incremental cost of non-fatal MI                                                                                                     
   Cost in first 90-day period                                                   5028              34.41            4961               £5096
   Cost in second 90-day period                                                  1282              36.84            1210               £1354
   Cost in third 90-day period                                                   675               39.15            598                £751
   Cost in fourth 90-day period                                                  692               40.84            612                £772
   Cost in subsequent 90-day periods                                             521               18.64            484                £557
  Additional incremental cost of non-fatal MI for patients with diabetes                                                               
   Additional cost in first 90-day period                                        776               75.79            627                924
   Cost in second 90-day period                                                  1100              81.56            940                1260
   Cost in third 90-day period                                                   785               87.01            614                955
   Cost in fourth 90-day period                                                  550               90.87            372                728
   Cost in subsequent 90-day periods                                             369               42.16            286                451
  Incremental cost of non-fatal ischaemic stroke                                                                                       
   Cost in first 90-day period                                                   6215              36.01            6144               6285
   Cost in second 90-day period                                                  1239              38.03            1164               1313
   Cost in third 90-day period                                                   795               41.05            714                875
   Cost in fourth 90-day period                                                  654               43.12            569                738
   Cost in subsequent 90-day periods                                             564               19.97            525                604
  Incremental cost of non-fatal haemorrhagic stroke                                                                                    
   Cost in first 90-day period                                                   7011              125.41           6765               7257
   Cost in second 90-day period                                                  1767              138.80           1495               2039
   Cost in third 90-day period                                                   947               155.22           643                1252
   Cost in fourth 90-day period                                                  751               165.14           428                1075
   Cost in subsequent 90-day periods                                             927               74.20            782                1073
  Cost of fatal events                                                                                                                 
   Fatal CVD event                                                               2008              24.88            1960               2057
   Fatal non-CVD event                                                           2240              20.16            2201               2280

###### 

Total cardiovascular disease-related healthcare costs

                                                                                 Coefficient (£)   Standard error   Lower 95% CI (£)   Upper 95% CI (£)
  ------------------------------------------------------------------------------ ----------------- ---------------- ------------------ ------------------
  Background cost per 90 days                                                                                                          
   Baseline (for a man aged 69 with stable angina and no other co-morbidities)   224               7.74             209                239
   Baseline age (centred)                                                        6                 0.32             6                  7
   Female                                                                        −23               7.65             −38                −8
   Increase per 90 days                                                          7                 0.15             6                  7
   SCAD diagnosis (relative to stable angina)                                                                                          
    Other CHD                                                                    2                 9.39             −16                21
    NSTEMI                                                                       145               13.66            119                172
    STEMI                                                                        29                15.77            −2                 60
    Unstable angina                                                              125               11.32            103                147
   CVD co-morbidities                                                                                                                  
    History of heart failure                                                     248               9.29             230                266
    History of atrial fibrillation                                               221               10.90            199                242
    History of PAD                                                               242               13.53            216                269
   Non-CVD co-morbidities                                                                                                              
    Diabetes                                                                     194               10.43            173                214
    History of liver disease                                                     279               38.68            203                355
    History of COPD                                                              142               8.79             124                159
    History of cancer                                                            154               13.34            128                180
    History of renal disease                                                     418               16.07            386                449
  Incremental cost of non-fatal MI                                                                                                     
   Cost in first 90-day period                                                   4854              29.55            4796               4911
   Cost in second 90-day period                                                  1209              31.64            1147               1271
   Cost in third 90-day period                                                   640               33.63            574                706
   Cost in fourth 90-day period                                                  675               35.08            606                744
   Cost in subsequent 90-day periods                                             481               15.64            451                512
  Additional incremental cost of non-fatal MI for patients with diabetes                                                               
   Additional cost in first 90-day period                                        674               65.05            546                801
   Cost in second 90-day period                                                  1042              70.02            904                1179
   Cost in third 90-day period                                                   660               74.71            514                807
   Cost in fourth 90-day period                                                  403               78.04            250                556
   Cost in subsequent 90-day periods                                             280               35.33            210                349
  Incremental cost of non-fatal ischaemic stroke                                                                                       
   Cost in first 90-day period                                                   5957              30.95            5897               6018
   Cost in second 90-day period                                                  1151              32.69            1087               1215
   Cost in third 90-day period                                                   675               35.29            606                744
   Cost in fourth 90-day period                                                  539               37.08            466                612
   Cost in subsequent 90-day periods                                             448               16.86            415                481
  Incremental cost of non-fatal haemorrhagic stroke                                                                                    
   Cost in first 90-day period                                                   6836              107.73           6625               7047
   Cost in second 90-day period                                                  1517              119.28           1284               1751
   Cost in third 90-day period                                                   585               133.45           324                847
   Cost in fourth 90-day period                                                  393               142.02           115                671
   Cost in subsequent 90-day periods                                             670               62.69            547                792
  Cost of fatal events                                                                                                                 
   Fatal CVD event                                                               2071              21.30            2029               2113
   Fatal non-CVD event                                                           1737              17.28            1703               1771

###### 

Total coronary heart disease-related healthcare costs

                                                                                 Coefficient (£)   Standard error   Lower 95% CI (£)   Upper 95% CI (£)
  ------------------------------------------------------------------------------ ----------------- ---------------- ------------------ ------------------
  Background cost per 90 days                                                                                                          
   Baseline (for a man aged 69 with stable angina and no other co-morbidities)   179               5.93             167                191
   Baseline age (centred)                                                        4                 0.24             4                  5
   Female                                                                        −23               5.85             −35                −12
   Increase per 90 days                                                          4                 0.12             3                  4
   SCAD diagnosis (relative to stable angina)                                                                                          
    Other CHD                                                                    82                7.17             68                 97
    NSTEMI                                                                       219               10.49            198                239
    STEMI                                                                        111               12.04            88                 135
    Unstable angina                                                              163               8.65             146                179
   CVD co-morbidities                                                                                                                  
    History of heart failure                                                     143               7.11             129                157
    History of atrial fibrillation                                               84                8.34             67                 100
    History of PAD                                                               161               10.35            141                181
   Non-CVD co-morbidities                                                                                                              
    Diabetes                                                                     144               7.98             128                160
    History of liver disease                                                     198               29.62            140                256
    History of COPD                                                              117               6.72             104                131
    History of cancer                                                            107               10.21            87                 127
    History of renal disease                                                     201               12.34            176                225
  Incremental cost of non-fatal MI                                                                                                     
   Cost in first 90-day period                                                   4658              23.69            4612               4705
   Cost in second 90-day period                                                  1166              25.36            1116               1215
   Cost in third 90-day period                                                   590               26.96            538                643
   Cost in fourth 90-day period                                                  642               28.13            587                697
   Cost in subsequent 90-day periods                                             475               12.40            451                500
  Additional incremental cost of non-fatal MI for patients with dibetes                                                                
   Additional cost in first 90-day period                                        643               52.14            541                745
   Cost in second 90-day period                                                  792               56.13            682                902
   Cost in third 90-day period                                                   701               59.90            584                819
   Cost in fourth 90-day period                                                  330               62.57            207                453
   Cost in subsequent 90-day periods                                             269               28.01            215                324
  Incremental cost of non-fatal ischaemic stroke                                                                                       
   Cost in first 90-day period                                                   3029              24.82            2981               3078
   Cost in second 90-day period                                                  620               26.22            568                671
   Cost in third 90-day period                                                   415               28.31            359                470
   Cost in fourth 90-day period                                                  262               29.74            203                320
   Cost in subsequent 90-day periods                                             256               13.42            230                282
  Incremental cost of non-fatal haemorrhagic stroke                                                                                    
   Cost in first 90-day period                                                   2874              86.38            2704               3043
   Cost in second 90-day period                                                  790               95.66            602                977
   Cost in third 90-day period                                                   218               107.04           8                  428
   Cost in fourth 90-day period                                                  301               113.92           77                 524
   Cost in subsequent 90-day periods                                             251               49.89            154                349
  Cost of fatal events                                                                                                                 
   Fatal CVD event                                                               1407              17.06            1374               1441
   Fatal non-CVD event                                                           1068              13.84            1040               1095

###### 

Covariate profiles based on deciles of 5-year risk

  ------------------------------------------------------------------------------------------------- ------- ------- ------- ------- -------- -------- -------- -------- -------- --------
  Patient average covariate profiles based on deciles of 5-year risk of composite CVD first event                                                                                
   Risk decile                                                                                      1       2       3       4       5        6        7        8        9        10
   5-year risk (average)                                                                            3.69%   5.70%   7.37%   9.15%   11.20%   13.71%   17.14%   22.14%   30.42%   52.37%
   Re-calculated 5-year risk                                                                        3.46%   5.43%   6.95%   8.53%   10.36%   12.57%   15.64%   20.07%   27.23%   44.18%
  Socio-demographic characteristics                                                                                                                                              
   Sex (female)                                                                                     64%     48%     42%     39%     37%      37%      38%      42%      44%      46%
   Age (if male)                                                                                    49      55      59      62      65       67       71       74       77       81
   Age (if female)                                                                                  53      62      67      70      73       75       78       80       83       87
   Age (weighted average)                                                                           52      59      62      65      68       70       73       76       80       84
   Most deprived quintile                                                                           15%     17%     18%     19%     20%      21%      21%      22%      22%      24%
  SCAD diagnosis and severity                                                                                                                                                    
   Other CHD                                                                                        11%     17%     20%     22%     24%      24%      25%      26%      25%      20%
   NSTEMI                                                                                           0%      1%      3%      5%      8%       10%      12%      17%      23%      43%
   STEMI                                                                                            1%      4%      8%      12%     13%      14%      13%      9%       6%       4%
   Unstable angina                                                                                  10%     13%     12%     12%     12%      12%      13%      15%      17%      15%
   Stable angina                                                                                    78%     65%     56%     49%     43%      39%      37%      34%      29%      18%
   PCI in last 6 months                                                                             9%      12%     13%     14%     13%      13%      11%      9%       6%       4%
   CABG in last 6 months                                                                            9%      7%      6%      5%      5%       4%       4%       3%       2%       1%
   Previous/recurrent MI                                                                            2%      6%      10%     14%     18%      23%      26%      29%      32%      43%
   Use of nitrates                                                                                  10%     16%     19%     21%     24%      28%      33%      37%      43%      56%
  CVD risk factors                                                                                                                                                               
   Current smoker                                                                                   31%     35%     36%     37%     38%      38%      37%      35%      32%      30%
   Ex-smoker                                                                                        27%     30%     31%     32%     32%      33%      34%      34%      34%      34%
   Never smoked                                                                                     41%     35%     33%     31%     30%      29%      29%      31%      33%      36%
   Hypertension                                                                                     69%     70%     71%     71%     72%      74%      76%      79%      83%      87%
   Diabetes                                                                                         4%      8%      10%     12%     14%      16%      18%      21%      24%      32%
   Total cholesterol (mmol/L)                                                                       4.95    4.91    4.84    4.79    4.74     4.74     4.70     4.68     4.64     4.54
   HDL (mmol/L)                                                                                     1.41    1.37    1.35    1.35    1.35     1.35     1.36     1.37     1.37     1.35
  CVD co-morbidities                                                                                                                                                             
   Heart failure                                                                                    5%      7%      9%      12%     15%      19%      27%      37%      52%      73%
   Peripheral arterial disease                                                                      1%      2%      3%      4%      6%       8%       10%      13%      16%      25%
   Atrial fibrillation                                                                              3%      5%      7%      9%      10%      13%      16%      21%      29%      43%
   Stroke                                                                                           0%      1%      1%      2%      3%       5%       8%       14%      22%      39%
  Non-CVD co-morbidities                                                                                                                                                         
   Chronic kidney disease                                                                           2%      2%      3%      4%      4%       5%       7%       9%       12%      20%
   Chronic obstructive pulmonary disease                                                            20%     20%     20%     21%     22%      23%      25%      27%      28%      30%
   Cancer                                                                                           4%      5%      6%      7%      8%       9%       11%      13%      14%      12%
   Chronic liver disease                                                                            0%      1%      1%      1%      1%       1%       1%       1%       1%       1%
  Psychosocial characteristics                                                                                                                                                   
   Depression at diagnosis                                                                          20%     17%     15%     15%     14%      14%      15%      17%      18%      21%
   Anxiety at diagnosis                                                                             7%      6%      6%      7%      7%       7%       8%       8%       10%      12%
  Biomarkers                                                                                                                                                                     
   Heart rate (b.p.m.)                                                                              72      71      71      71      71       71       72       73       74       76
   Creatinine (mmol/L)                                                                              88      92      95      96      98       100      101      104      109      125
   White cell count (10^9^/L)                                                                       6.81    7.05    7.19    7.31    7.44     7.54     7.62     7.76     7.88     8.22
   Haemoglobin (g/100 mL)                                                                           14.26   14.26   14.16   14.05   13.88    13.70    13.48    13.16    12.81    12.20
  ------------------------------------------------------------------------------------------------- ------- ------- ------- ------- -------- -------- -------- -------- -------- --------
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